News
🇺🇸 AmericasLatest pharmaceutical news, drug approvals, and FDA regulatory updates
Latest News
OSE Immunotherapeutics' Pegrizeprument (VEL-101) Receives FDA Orphan Drug Designation for Heart Transplant Rejection Prevention
OSE Immunotherapeutics announces FDA Orphan Drug Designation for pegrizeprument (VEL-101) to prevent heart transplant rejection, following liver designation.
Jazz Pharmaceuticals' Ziihera Gets FDA Priority Review for First-Line HER2+ Cancer Treatment
Jazz Pharmaceuticals receives FDA Priority Review for Ziihera (zanidatamab-hrii) combinations in first-line HER2+ cancer with August 2026 PDUFA date.
NCCN Adds Nuvation Bio's Taletrectinib (IBTROZI) to Cancer Treatment Guidelines for ROS1-Positive NSCLC with Brain Metastases
NCCN includes Nuvation Bio's taletrectinib as recommended treatment option for ROS1-positive non-small cell lung cancer patients with brain metastases.
FDA Grants Priority Review for IMAAVY (Nipocalimab-aahu) as First Potential Treatment for Warm Autoimmune Hemolytic Anemia
FDA grants Priority Review for IMAAVY (nipocalimab-aahu), potentially the first approved treatment for warm autoimmune hemolytic anemia (wAIHA).
FDA Approves Johnson & Johnson's CAPLYTA (Lumateperone) sNDA for Schizophrenia Relapse Prevention
FDA approves CAPLYTA supplemental application showing 63% relapse risk reduction in schizophrenia patients with 84% remaining relapse-free over six months.
Apotex Receives FDA Approval for Generic Infuvite Pediatric Injection with 180-Day Exclusivity
Apotex announces FDA approval of generic Infuvite Pediatric Injection with 180-day CGT exclusivity, expanding pediatric vitamin therapy options.
Clinical Outsourcing Group: Pharma News Roundup (April 28, 2026)
Pharma news roundup for April 28, 2026, focusing on clinical manufacturing, cancer therapy data, and outsourcing trends. Minaris achieved 100% manufacturing success with Chimeric Therapeutics' CAR-T program, and Sona Nanotech presented positive data on Targeted Hyperthermia Therapy.
4th Annual COG 2026: No Major Pharma News Today
No breaking pharmaceutical or oncology news was identified from the 4th Annual COG 2026 event as of April 28, 2026. The event's official status and details could not be verified from available sources.
Pharma Compliance Congress: Key Takeaways Day 1
The Pharmaceutical Compliance Congress Day 1 highlighted evolving FDA regulatory priorities, including manufacturing quality, data integrity, and supply chain security. Industry leaders emphasized the importance of robust quality management systems and cross-functional collaboration in maintaining pharmaceutical compliance.
ACRP 2026: Patient-Centric Trials & Workforce Expansion
ACRP 2026 Annual Conference (April 27–29, Orlando) prioritized clinical operations and workforce development over immunology trial announcements. Key themes included patient-centric trials using Net Treatment Benefit frameworks, workforce expansion initiatives, and e-regulatory binder adoption strategies.
Pharma Compliance Congress: Key Regulatory Updates Day 1
The Pharmaceutical Compliance Congress convened industry professionals on Day 1 to address evolving FDA guidance, compliance strategy optimization, and best practices for managing regulatory risk in pharmaceutical manufacturing and commercialization.
Testosterone Therapy FDA Update: Key Regulatory Advances
The FDA has announced important regulatory advancements on testosterone therapy for men, focusing on improved safety monitoring and updated approval processes. Learn what this means for testosterone deficiency treatment.
GLP-1 Eating Disorder Risk: What You Need to Know
Recent concerns about GLP-1 receptor agonists like semaglutide highlight potential eating disorder risks. This article reviews current evidence, FDA stance, and safety considerations.
AACR 2026: AI Pathology & Oncolytic Virus Spark Interest
AACR 2026 in San Diego showcased Path-IO, an AI pathomics model outperforming PD-L1 in NSCLC immunotherapy stratification, and VCN-01 oncolytic virus data demonstrating improved responses in metastatic pancreatic cancer clinical trials.
INTERPHEX 2026: Phillips Medisize's Embedded Sensing Tech
At INTERPHEX 2026, Phillips Medisize unveiled embedded sensing technology that transforms single-use bioprocessing systems into data-rich assets, enabling real-time monitoring of pH, dissolved oxygen, and metabolites while maintaining sterile, closed-system manufacturing environments.
Pharma Compliance Congress: Day 1 Key Regulatory Updates
The Pharmaceutical Compliance Congress Day 1 brought together industry leaders to discuss evolving FDA compliance requirements, data-driven compliance strategies, and practical approaches to maintaining regulatory adherence in pharmaceutical operations.
Ascletis Completes Enrollment for ASC30 Oral GLP-1 Diabetes Drug Phase II Trial
Ascletis Pharma completes enrollment in Phase II trial of ASC30, an oral GLP-1 receptor agonist for diabetes treatment, with results expected Q3 2026.
Ascletis Completes Enrollment in Phase II Trial of ASC30 Oral GLP-1 Diabetes Drug
Ascletis Pharma completes enrollment of 100 patients in Phase II trial of ASC30, an oral GLP-1 receptor agonist for diabetes treatment, with results expected Q3 2026.
Sun Pharma Acquires Organon for $11.75 Billion in Major Pharmaceutical Merger
Sun Pharmaceutical Industries announces $11.75 billion acquisition of Organon at $14 per share, creating global pharmaceutical powerhouse.
Boston Scientific FARAPULSE and WATCHMAN Show Positive Safety Data at Heart Rhythm 2026
Boston Scientific presents positive clinical trial data for FARAPULSE Pulsed Field Ablation and WATCHMAN devices at Heart Rhythm 2026 conference.